TED MURRAY DAWSON, M.D.
Neurology at Wolfe St, Baltimore, MD
License number
Maryland D40127
Category
Neurology
Type
Neurology
Address
Address
600 N Wolfe St, Baltimore, MD 21287
Phone
(410) 955-9441
Personal information
See more information about TED MURRAY DAWSON at radaris.comName
Address
Phone
5612 Saint Albans Way, Baltimore, MD 21212
41 Tailwinds Ln, North East, MD 21901
5612 Saint Albans Rd, Baltimore, MD 21212
Professional information
Ted Murray Dawson, Baltimore MD
Specialties:
Neurologist
Address:
600 N Wolfe St, Baltimore, MD 21287
600 N Wolfe, Baltimore, MD 21287
733 N Broadway, Baltimore, MD 21205
600 N Wolfe, Baltimore, MD 21287
733 N Broadway, Baltimore, MD 21205
Education:
University of Utah, School of Medicine - Doctor of Medicine
University of Utah - Doctor of Philosophy
Johns Hopkins Hospital - Fellowship - Movement Disorders
Hospital of the University of Pennsylvania - Residency - Neurology
University of Utah - Doctor of Philosophy
Johns Hopkins Hospital - Fellowship - Movement Disorders
Hospital of the University of Pennsylvania - Residency - Neurology
Board certifications:
American Board of Psychiatry and Neurology Certification in Neurology (Psychiatry and Neurology)
Method Of Using Selective Parp Inhibitors To Prevent Or Treat Neurotoxicity
US Patent:
6358975, Mar 19, 2002
Filed:
Feb 11, 2000
Appl. No.:
09/502046
Inventors:
Mikael J. Eliasson - Baltimore MD
Kenji Sampei - Baltimore MD
Allen S. Mandir - Baltimore MD
Patricia D. Hurn - Upperco MD
Richard J. Traystman - Ruxton MD
Jun Bao - Baltimore MD
Andrew Pieper - Baltimore MD
Ted M. Dawson - Baltimore MD
Solomon Snyder - Baltimore MD
Valina L. Dawson - Baltimore MD
Kenji Sampei - Baltimore MD
Allen S. Mandir - Baltimore MD
Patricia D. Hurn - Upperco MD
Richard J. Traystman - Ruxton MD
Jun Bao - Baltimore MD
Andrew Pieper - Baltimore MD
Ted M. Dawson - Baltimore MD
Solomon Snyder - Baltimore MD
Valina L. Dawson - Baltimore MD
Assignee:
Johns Hopkins University - Baltimore MD
International Classification:
A61K 3147
US Classification:
514309, 514617, 514619
Abstract:
Neutral tissue damage resulting for ischemia and reperfusion injury or neurodegenerative diseases can be prevented by administering therapeutically effective amounts of certain selective inhibitors of poly(ADP-ribose)polymerase. The inhibitors can be administered intravenously, intraperitoneally, intramuscularly, intraventricularly, or orally. They can be administered as a capsule or tablet containing single or divided dose. Alternatively, the inhibitors can be administered as a sterile solution, suspension or emulsion.
Treatment And Prevention Of Pathological Conditions Using Iduna Related Techniques And Compositions
US Patent:
2012012, May 17, 2012
Filed:
Nov 11, 2011
Appl. No.:
13/294884
Inventors:
Ted M. Dawson - Baltimore MD, US
Valina L. Dawson - Baltimore MD, US
Shaida A. Andrabi - Baltimore MD, US
Ho Chul Kang - Parkville MD, US
Valina L. Dawson - Baltimore MD, US
Shaida A. Andrabi - Baltimore MD, US
Ho Chul Kang - Parkville MD, US
International Classification:
A61K 48/00, A61K 31/7105, A61P 7/02, A61P 35/00, A61P 25/28, A61P 9/10, A61K 31/7088, C12Q 1/68
US Classification:
424 9321, 514 44 A, 514 44 R, 435 61
Abstract:
Research into neuroprotective mechanisms has at its heart the goal of developing new therapeutic strategies to treat patients. For example, the compositions and induction strategies disclosed herein have use for acute injuries such as stroke or trauma, and would be extremely useful in treating patients undergoing cardiac bypass surgery, neurosurgery or other surgical cohorts where ischemia is a risk. Further, patients with subarachnoid hemorrhage, transient ischemic attacks, soldiers at risk for blast injury or patients suffering from chronic neurodegenerative diseases would also benefit from enhanced neuronal survival based upon the techniques and compositions disclosed herein. In addition, protecting against cell death by, for example, interfering with PAR polymer signaling via the compositions and processes disclosed herein, offers new therapeutic strategies for the treatment of neurologic disorders.
Compounds And Related Methods For Manipulating Parp-1-Dependent Cell Death
US Patent:
2012012, May 17, 2012
Filed:
Nov 11, 2011
Appl. No.:
13/294938
Inventors:
Ted M. Dawson - Baltimore MD, US
Valina L. Dawson - Baltimore MD, US
Yingfei Wang - Baltimore MD, US
Valina L. Dawson - Baltimore MD, US
Yingfei Wang - Baltimore MD, US
International Classification:
A61K 38/17, C12N 15/12, A61P 25/00, A61P 25/28, A61P 3/10, A61P 27/02, A61P 13/12, A61P 9/00, A61P 9/10, A61P 35/00, A61P 9/04, A61P 25/16, A61P 25/14, A61P 19/02, A61P 1/00, C12N 15/63, C12P 21/02, C12N 1/21, C12N 1/19, C12N 5/10, C12Q 1/68, C07K 14/435
US Classification:
514 19, 530324, 530326, 536 235, 514 177, 514 178, 514 179, 514 69, 514 208, 514 154, 514 164, 514 151, 514 193, 514 167, 4353201, 435 691, 43525233, 43525231, 43525234, 4352523, 4352542, 435325, 435348, 435 61
Abstract:
Apoptosis inducing factor (“AIF”) contains a PAR-binding motif (“PBM”) that binds to Poly(ADP-ribose) (“PAR”). Binding of PAR to AIF via the PBM is required for AIF release from the mitochondria to occur, and that this PAR-related release is a key step in the programmed cell death process known as parthanatos, both in vitro and in vivo. Preventing or disrupting this release can inhibit parthanatos and thus be the basis for treatments for patients suffering from diseases or medical conditions during which parthanatos commonly occurs, including Parkinson's disease or diabetes, or patients who have had and are recovering from heart attack, stroke and other ischemia reperfusion-related injuries. Alternatively, agents could be identified that enhance the release of AIF, thereby promoting parthanatos and serving as potential anti-tumor chemotherapeutic agents.
Direct Influences On Nerve Growth Of Agents That Interact With Immunophilins In Combination With Neurotrophic Factors
US Patent:
5898029, Apr 27, 1999
Filed:
Apr 12, 1994
Appl. No.:
8/229601
Inventors:
W. Ernest Lyons - Columbia MD
Edwin B. George - Baltimore MD
Ted M. Dawson - Baltimore MD
Joseph P. Steiner - Hampstead MD
Solomon H. Snyder - Baltimore MD
Edwin B. George - Baltimore MD
Ted M. Dawson - Baltimore MD
Joseph P. Steiner - Hampstead MD
Solomon H. Snyder - Baltimore MD
Assignee:
The John Hopkins University - Baltimore MD
International Classification:
A61K 3818, A61K 31435
US Classification:
514 12
Abstract:
Immunophilin ligands act by binding to receptor proteins, immunophilins, which in turn can bind to and regulate the Ca. sup. 2+ dependent phosphatase, calcineurin, and the Ca. sup. 2+ release channel, the ryanodine receptor. Immunophilin ligands have been discovered to enhance neurite outgrowth in neuronal cell systems by increasing sensitivity to neurotrophic factors. The effects of the immunophilin ligands are detected at subnanomolar concentrations indicating therapeutic application in diseases involving neural degeneration.
Inhibitors Of Nitric Oxide Synthase And Use Thereof To Prevent Glutamate Neurotoxicity
US Patent:
5266594, Nov 30, 1993
Filed:
May 12, 1992
Appl. No.:
7/881900
Inventors:
Valina L. Dawson - Baltimore MD
Ted M. Dawson - Baltimore MD
Edythe D. London - Baltimore MD
David S. Bredt - Baltimore MD
Solomon H. Snyder - Baltimore MD
Ted M. Dawson - Baltimore MD
Edythe D. London - Baltimore MD
David S. Bredt - Baltimore MD
Solomon H. Snyder - Baltimore MD
International Classification:
A61K 3120
US Classification:
514560
Abstract:
Inhibitors of nitric acid synthase can be used to prevent neurotoxicity mediated through glutamate receptors. Nitric oxide synthase inhibitors can be used therapeutically in the treatment of vascular stroke and neurodegenerative disorders such as Alzheimer's disease and Huntington's disease.
Inhibitors Of Rotamase Enzyme Activity
US Patent:
5843960, Dec 1, 1998
Filed:
Jan 23, 1997
Appl. No.:
8/787162
Inventors:
Joseph P. Steiner - Hampstead MD
Solomon Snyder - Baltimore MD
Gregory S. Hamilton - Catonsville MD
Ted Dawson - Baltimore MD
Solomon Snyder - Baltimore MD
Gregory S. Hamilton - Catonsville MD
Ted Dawson - Baltimore MD
Assignee:
GPI Nil Holdings, Inc. - Wilmington DE
Johns Hopkins University School of Medicine - Baltimore MD
Johns Hopkins University School of Medicine - Baltimore MD
International Classification:
A61K 31445, A61K 3818
US Classification:
514317
Abstract:
This invention relates to the method of using neurotrophic pipecolic acid derivative compounds having an affinity for FKBP-type immunophilins as inhibitors of the enzyme activity associated with immunophilin proteins, and particularly inhibitors of peptidyl-prolyl isomerase or rotamase enzyme activity to stimulate or promote neuronal growth or regeneration.
Stimulating Nerve Growth With Immunophilins
US Patent:
6080753, Jun 27, 2000
Filed:
Sep 15, 1997
Appl. No.:
8/931070
Inventors:
W. Ernest Lyons - Columbia MD
Edwin B. George - Baltimore MD
Ted M. Dawson - Baltimore MD
Joseph P. Steiner - Hampstead MD
Solomon H. Snyder - Baltimore MD
Edwin B. George - Baltimore MD
Ted M. Dawson - Baltimore MD
Joseph P. Steiner - Hampstead MD
Solomon H. Snyder - Baltimore MD
Assignee:
Johns Hopkins University School of Medicine - Baltimore MD
International Classification:
A61K 31435, A61K 3144
US Classification:
514291
Abstract:
Immunophilin ligands act by binding to receptor proteins, immunophilins, which in turn can bind to and regulate the Ca. sup. 2+ dependent phosphatase, calcineurin, and the Ca. sup. 2+ release channel, the ryanodine receptor. Immunophilin ligands have been discovered to enhance neurite outgrowth in neuronal cell systems by increasing sensitivity to neurotrophic factors. The effects of the immunophilin ligands are detected at subnanomolar concentrations indicating therapeutic application in diseases involving neural degeneration.
Methods Of Making And Using Thioxothiazolidine And Rhodanine Derivatives As Hiv-1 And Jsp-1 Inhibitors
US Patent:
2013025, Sep 26, 2013
Filed:
Mar 22, 2013
Appl. No.:
13/849339
Inventors:
Ted M. Dawson - Baltimore MD, US
Assignee:
The Johns Hopkins University - Baltimore MD
Southern Methodist University - Dallas TX
Southern Methodist University - Dallas TX
International Classification:
C07D 277/34, C07D 277/62
US Classification:
514367, 435184, 514369, 548181, 548183
Abstract:
The present invention provides methods of making and using 5-(2-(indol-3-yl)-2-oxoethylidene)-3-phenyl-2-thioxothiazolidin-4-one derivatives having HIV-1 or JSP-1 inhibitory activity.
Inhibitors Of Rotamase Enzyme Activity
US Patent:
5846981, Dec 8, 1998
Filed:
Jan 23, 1997
Appl. No.:
8/787163
Inventors:
Joseph P. Steiner - Hampstead MD
Solomon Snyder - Baltimore MD
Gregory S. Hamilton - Catonsville MD
Ted Dawson - Baltimore MD
Solomon Snyder - Baltimore MD
Gregory S. Hamilton - Catonsville MD
Ted Dawson - Baltimore MD
Assignee:
GPI NIL Holdings Inc. - Wilmington DE
Johns Hopkins University School of Medicine - Baltimore MD
Johns Hopkins University School of Medicine - Baltimore MD
International Classification:
A61K 31445, A61K 3818
US Classification:
514317
Abstract:
This invention relates to the method of using neurotrophic pipecolic acid derivative compounds having an affinity for FKBP-type immunophilins as inhibitors of the enzyme activity associated with immunophilin proteins, and particularly inhibitors of peptidyl-prolyl isomerase or rotamase enzyme activity to stimulate or promote neuronal growth or regeneration.